Table 3.
Primary and secondary outcomes.
| Variables | Baseline | Follow-Up | p Value |
|---|---|---|---|
| PRIMARY OUTCOME | |||
| PeakVO2 (mL/kg/min) | |||
| Sac/Val | 12.2 ± 4.6 | 12.7 ± 3.3 | 0.49 |
| Control group | 13.1 ± 4.2 | 13.0 ± 4.2 | |
| SECONDARY OUTCOMES | |||
| VE/VCO2 slope | |||
| Sac/Val | 35.4 ± 7.4 | 37.2 ± 13.1 | 0.49 |
| Control group | 34.6 ± 9.1 | 34.0 ± 7.3 | |
| Predicted VO2 peak (%) | |||
| Sac/Val | 61.5 ± 25.7 | 67.0 ± 23.7 | 0.53 |
| Control group | 59.2 ± 20.7 | 61.1 ± 23.9 | |
| LVEF (%) | |||
| Sac/Val | 30.7 ± 4.0 | 36.1 ± 4.8 | 0.06 |
| Control group | 32.3 ± 5.1 | 33.1 ± 7.8 | |
| LVEDVi (mL/m2) | |||
| Sac/Val | 116.0 ± 36.9 | 80.3 ± 19.1 | 0.09 |
| Control group | 129.6 ± 32.4 | 125.0 ± 37.2 | |
| LVESVi (mL/m2) | |||
| Sac/Val | 80.6 ± 27.9 | 51.5 ± 15.8 | 0.08 |
| Control group | 86.0 ± 33.7 | 89.2 ± 31.0 | |
| E/e’ ratio | |||
| Sac/Val | 16.0 ± 7.5 | 13.0 ± 10.0 | 0.07 |
| Control group | 15.2 ± 9.5 | 13.9 ± 10.0 | |
| LAVi (ml/m2) | |||
| Sac/Val | 44.2 ± 15.4 | 42.8 ± 5.3 | 0.7 |
| Control group | 46.8 ± 15.6 | 43.8 ± 14.7 | |
| TAPSE (mm) | |||
| Sac/Val | 17.5 (16.2–21.2) | 20 (19–22) | 0.4 |
| Control group | 18 (16.0–21.5) | 20.5 (17.8–22.2) | |
| sPAP (mmHg) | |||
| Sac/Val | 32.1 ± 8.7 | 33.9 ± 10.4 | 0.17 |
| Control group | 39.2 ± 9.6 | 36.7 ± 12.3 | |
| SBP (mmHg) | |||
| Sac/Val | 110 (110–130) | 100 (925–110) | 0.07 |
| Control group | 115 (110–125) | 110 (100–125) | |
Sac/Val: sacubitril/valsartan; VO2: oxygen consumption; VE/VCO2: minute ventilation to carbon dioxide production; LVEF: left ventricular ejection fraction; LVEDVi: left ventricular end-diastolic volume index; LVESVi: left ventricular end-systolic volume index; E: early-wave transmitral diastolic velocity; e’: early-diastolic velocity at tissue Doppler imaging; LAVi: left atrial volume index; TAPSE: tricuspid annular plane systolic excursion; sPAP: pulmonary artery systolic pressure; SBP: systolic blood pressure.